Home › Companies › VSTM

Verastem

VSTM Lead: Approved 1 Biotech Distilled article ↓

Oncology Small Molecule

Most recent annual filing: 2026-03-04

Pipeline (5 active programs)

AVMAPKI

FAKZYNJA · AVMAPKI FAKZYNJA CO-PACK · avutometinib · defactinib

Small Molecule Target: RAF, MEK, FAK

Low-Grade Serous Ovarian Cancer Approved oral Chugai Pharmaceutical

AVMAPKI

FAKZYNJA · avutometinib · defactinib

Small Molecule Target: RAF, MEK, FAK

Pancreatic Ductal Adenocarcinoma Phase 2 oral

VS-7375

Small Molecule Target: KRAS G12D

Pancreatic Ductal Adenocarcinoma Phase 1 oral GenFleet Therapeutics
Non-Small Cell Lung Cancer Phase 1 oral GenFleet Therapeutics
Colorectal Cancer Phase 1 oral GenFleet Therapeutics

Discontinued (1)

avutometinib — Non-Small Cell Lung Cancer · discontinued RAMP 203 to focus resources on VS-7375 development; evolving treatment landscape for KRAS G12C inhibitors

Biotech Distilled coverage (1)

2026-07-20 Verastem Oncology (VSTM) — Scientific Deep Dive for AVMAPKI FAKZYNJA CO-PACK (Avutometinib + Defactinib) and VS-7375 (Oral KRAS G12D)

Articles open on Substack. Some deep dives are subscriber-only.